{"id":69933,"date":"2026-07-14T14:36:24","date_gmt":"2026-07-14T06:36:24","guid":{"rendered":"https:\/\/flcube.com\/?p=69933"},"modified":"2026-07-14T14:36:25","modified_gmt":"2026-07-14T06:36:25","slug":"gsk-terminates-2-2-billion-neurodegenerative-disease-partnership-with-alector-following-dual-clinical-failures","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69933","title":{"rendered":"GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>GlaxoSmithKline plc (GSK)<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE: GSK<\/a>) has formally terminated its <strong>neurodegenerative disease research collaboration<\/strong> with <strong>Alector<\/strong>, originally established in 2021 with a total potential value exceeding <strong>USD 2.2 billion<\/strong>. The decision follows consecutive clinical failures of both pipeline assets targeting the progranulin pathway for frontotemporal dementia (FTD) and Alzheimer&#8217;s disease.<\/p>\n\n\n\n<h2 id=\"h-partnership-termination-details\" class=\"wp-block-heading\">Partnership Termination Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Terminating Party<\/strong><\/td><td>GlaxoSmithKline plc (GSK)<\/td><\/tr><tr><td><strong>Counterparty<\/strong><\/td><td>Alector<\/td><\/tr><tr><td><strong>Original Agreement Date<\/strong><\/td><td>2021<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td>&gt;$2.2 billion (including milestones)<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>$700 million (now written off by GSK)<\/td><\/tr><tr><td><strong>Unrealized Milestones<\/strong><\/td><td>$1.5 billion in biobucks (permanently forfeited by Alector)<\/td><\/tr><tr><td><strong>Termination Date<\/strong><\/td><td>Monday, July 12, 2026<\/td><\/tr><tr><td><strong>Disclosure<\/strong><\/td><td>SEC filing (week of July 14, 2026)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-pipeline-asset-failures\" class=\"wp-block-heading\">Pipeline Asset Failures<\/h2>\n\n\n\n<h3 id=\"h-latozinemab-phase-iii-frontotemporal-dementia-study\" class=\"wp-block-heading\">Latozinemab \u2013 Phase III Frontotemporal Dementia Study<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indication:<\/strong> Various forms of frontotemporal dementia (FTD)<\/li>\n\n\n\n<li><strong>Trial Outcome:<\/strong> Failed to slow disease progression (2025)<\/li>\n\n\n\n<li><strong>Consequence:<\/strong> Alector discontinued development and reduced workforce by 50%<\/li>\n\n\n\n<li><strong>Strategic Impact:<\/strong> Cast significant doubt on progranulin-targeting approach viability<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-nivisnebart-phase-ii-alzheimer-s-disease-study\" class=\"wp-block-heading\">Nivisnebart \u2013 Phase II Alzheimer&#8217;s Disease Study<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indication:<\/strong> Alzheimer&#8217;s disease<\/li>\n\n\n\n<li><strong>Trial Outcome:<\/strong> Halted in April 2026 after deemed unlikely to meet primary endpoint<\/li>\n\n\n\n<li><strong>Primary Endpoint:<\/strong> Slowing disease progression<\/li>\n\n\n\n<li><strong>Consequence:<\/strong> Effectively ended partnership prospects before formal termination<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Both therapies were designed to boost progranulin levels to regulate brain immune activity and support neuronal function through sortilin-targeting mechanisms.<\/p>\n\n\n\n<h2 id=\"h-financial-amp-strategic-implications\" class=\"wp-block-heading\">Financial &amp; Strategic Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Stakeholder<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>GSK<\/strong><\/td><td>$700 million upfront payment written off; strategic refocus away from progranulin pathway<\/td><\/tr><tr><td><strong>Alector<\/strong><\/td><td>Loss of $1.5 billion in potential milestone payments; significant cash runway reduction<\/td><\/tr><tr><td><strong>Investors<\/strong><\/td><td>Stock price volatility expected; reassessment of neurodegenerative disease investment thesis<\/td><\/tr><tr><td><strong>Industry<\/strong><\/td><td>Questions raised about progranulin as viable therapeutic target for neurodegenerative conditions<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>Competitors may accelerate alternative approaches to FTD and Alzheimer&#8217;s disease<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The neurodegenerative disease space continues to present significant challenges, with over 99% of Alzheimer&#8217;s drug candidates failing in clinical development. The dual failure of GSK and Alector&#8217;s progranulin-targeting approach underscores the complexity of modulating brain immune pathways for therapeutic benefit.<\/p>\n\n\n\n<h2 id=\"h-market-context-amp-forward-outlook\" class=\"wp-block-heading\">Market Context &amp; Forward Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Neurodegenerative Disease Market:<\/strong> Despite high failure rates, the global market for Alzheimer&#8217;s and FTD treatments remains attractive, projected at $15+ billion by 2030<\/li>\n\n\n\n<li><strong>GSK Strategy:<\/strong> Likely to redirect resources toward more promising platforms in its neuroscience pipeline or external partnerships with validated mechanisms<\/li>\n\n\n\n<li><strong>Alector Position:<\/strong> Faces critical juncture requiring either new partnerships, asset sales, or strategic alternatives to maintain operations<\/li>\n\n\n\n<li><strong>Scientific Implications:<\/strong> Progranulin pathway may require more sophisticated modulation approaches or patient stratification strategies to demonstrate clinical benefit<\/li>\n\n\n\n<li><strong>Investor Sentiment:<\/strong> Increased caution expected toward early-stage neurodegenerative disease programs without robust biomarker validation<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding strategic implications, market dynamics, and financial impacts of the GSK-Alector partnership termination. Actual results may differ due to risks including competitive developments, regulatory decisions, and scientific advances in neurodegenerative disease research.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GlaxoSmithKline plc (GSK) (NYSE: GSK) has formally terminated its neurodegenerative disease research collaboration with Alector,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4855,278,184,914],"class_list":["post-69933","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-alector","tag-glaxosmithkline","tag-gsk","tag-nyse-gsk"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GlaxoSmithKline plc (GSK) (NYSE: GSK) has formally terminated its neurodegenerative disease research collaboration with Alector, originally established in 2021 with a total potential value exceeding USD 2.2 billion. The decision follows consecutive clinical failures of both pipeline assets targeting the progranulin pathway for frontotemporal dementia (FTD) and Alzheimer&#039;s disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69933\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures\" \/>\n<meta property=\"og:description\" content=\"GlaxoSmithKline plc (GSK) (NYSE: GSK) has formally terminated its neurodegenerative disease research collaboration with Alector, originally established in 2021 with a total potential value exceeding USD 2.2 billion. The decision follows consecutive clinical failures of both pipeline assets targeting the progranulin pathway for frontotemporal dementia (FTD) and Alzheimer&#039;s disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69933\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-14T06:36:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-14T06:36:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69933#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69933\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures\",\"datePublished\":\"2026-07-14T06:36:24+00:00\",\"dateModified\":\"2026-07-14T06:36:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69933\"},\"wordCount\":453,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Alector\",\"GlaxoSmithKline\",\"GSK\",\"NYSE: GSK\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69933#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69933\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69933\",\"name\":\"GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-14T06:36:24+00:00\",\"dateModified\":\"2026-07-14T06:36:25+00:00\",\"description\":\"GlaxoSmithKline plc (GSK) (NYSE: GSK) has formally terminated its neurodegenerative disease research collaboration with Alector, originally established in 2021 with a total potential value exceeding USD 2.2 billion. The decision follows consecutive clinical failures of both pipeline assets targeting the progranulin pathway for frontotemporal dementia (FTD) and Alzheimer's disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69933#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69933\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69933#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures - Insight, China&#039;s Pharmaceutical Industry","description":"GlaxoSmithKline plc (GSK) (NYSE: GSK) has formally terminated its neurodegenerative disease research collaboration with Alector, originally established in 2021 with a total potential value exceeding USD 2.2 billion. The decision follows consecutive clinical failures of both pipeline assets targeting the progranulin pathway for frontotemporal dementia (FTD) and Alzheimer's disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69933","og_locale":"en_US","og_type":"article","og_title":"GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures","og_description":"GlaxoSmithKline plc (GSK) (NYSE: GSK) has formally terminated its neurodegenerative disease research collaboration with Alector, originally established in 2021 with a total potential value exceeding USD 2.2 billion. The decision follows consecutive clinical failures of both pipeline assets targeting the progranulin pathway for frontotemporal dementia (FTD) and Alzheimer's disease.","og_url":"https:\/\/flcube.com\/?p=69933","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-14T06:36:24+00:00","article_modified_time":"2026-07-14T06:36:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69933#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69933"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures","datePublished":"2026-07-14T06:36:24+00:00","dateModified":"2026-07-14T06:36:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69933"},"wordCount":453,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Alector","GlaxoSmithKline","GSK","NYSE: GSK"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69933#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69933","url":"https:\/\/flcube.com\/?p=69933","name":"GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-14T06:36:24+00:00","dateModified":"2026-07-14T06:36:25+00:00","description":"GlaxoSmithKline plc (GSK) (NYSE: GSK) has formally terminated its neurodegenerative disease research collaboration with Alector, originally established in 2021 with a total potential value exceeding USD 2.2 billion. The decision follows consecutive clinical failures of both pipeline assets targeting the progranulin pathway for frontotemporal dementia (FTD) and Alzheimer's disease.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69933#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69933"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69933#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69933"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69933\/revisions"}],"predecessor-version":[{"id":69934,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69933\/revisions\/69934"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69933"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69933"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}